Bydureon (by-DUR-ee-on), a new long-acting form of Byetta (exenatide) for type 2 diabetes

March 2012

You'll see Bydureon (by-DUR-ee-on), a new long-acting form of Byetta (exenatide) for type 2 diabetes.

Bydureon is injected just once a WEEK...compared to twice a day for Byetta or once a day for Victoza (liraglutide).

These glucagon-like peptide-1 (GLP-1) agonists are often added to oral meds to improve glycemic control and help patients lose weight.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote